To standardize and guide the implementation of clinical trials of recombinant human coagulation factor VIII and IX products, and promote the virtuous development of such products, NMPA organized the formulation of the Technical Guidelines for Clinical Trial of Recombinant Human Coagulation Factor VIII and the Technical Guidelines for Clinical Trial of Recombinant Human Coagulation Factor IX, which were issued on June 11, 2019.